Novartis AG (NVS) is expected to report earnings on Tuesday, October 27, 2026, after the close. Consensus EPS estimate is $2.24.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-21 | FY2026 Q2 | $2.17 | $2.41 | +11.1% | $14.42B |
| 2026-04-28 | FY2026 Q1 | $2.11 | $1.65 | -21.8% | $13.52B |
| 2026-02-04 | FY2025 Q4 | $1.99 | $2.03 | +2.0% | $13.33B |
| 2025-10-27 | FY2025 Q3 | $2.26 | $2.25 | -0.4% | $14.36B |
| 2025-07-17 | FY2025 Q2 | $2.38 | $2.42 | +1.7% | $14.84B |
| 2025-03-31 | FY2025 Q1 | $2.12 | $2.28 | +7.5% | $13.62B |
| 2025-01-31 | FY2024 Q4 | $1.80 | $1.98 | +10.0% | $13.56B |
| 2024-09-30 | FY2024 Q3 | $1.94 | $2.06 | +6.2% | $13.17B |
NVS has beaten consensus EPS in 6 of its last 8 reported quarters.
See NVS on the live calendar →